3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Rheumatoid Arthritis, Systemic Juvenile
1
Rectal Neoplasms
1
Periodic Fevers Syndrome
1
Neoplasms
1
Mevalonate Kinase Deficiency
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Cryopyrin-Associated Periodic Syndromes
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ductal
1
Carcinoma
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Arthritis, Juvenile
1
Arthralgia
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
Carboplatin
30
Cisplatin
23
pembrolizumab
22
Paclitaxel
21
Pemetrexed
20
Gemcitabine
10
osimertinib
9
durvalumab
9
Nivolumab
9
130-nm albumin-bound paclitaxel
8
Sunitinib
7
Sorafenib
7
Fluorouracil
7
Everolimus
7
Docetaxel
7
Axitinib
7
Cetuximab
6
epothilone B
5
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
5
volociximab
4
trebananib
4
reolysin
4
catumaxomab
4
cabozantinib
4
atezolizumab
4
Radiotherapy
4
Ipilimumab
4
vosaroxin
3
liposomal doxorubicin
3
lenvatinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma
×
canakinumab
×
Clear all
NCT03626545
2023-08-21
CANOPY-2
Novartis
Phase 3
Terminated
245 enrolled
29 charts